Exploratory secondary analysis of the GOLMePsA trial: whole-body MRI in 31 people with early, treatment-naïve PsA showed widespread low-intensity peripheral inflammation, improving by weeks 24 and 36 with no difference between MTX plus golimumab and MTX alone.
Secondary analysisn = 31
De Marco et al. Whole body-MRI identifies widespread, low intensity inflammation in peripheral joints, and axial involvement in a third of patients with early, treatment-naïve, active PsA: data from the GOLMePsA clinical trial